Glycoprotein IIbIIIa Antagonists in Acute Coronary Syndromes Undergoing PCI : A Long Way to Select Optimal Agent and Route
المؤلفون المشاركون
Bugiardini, Raffaele
Schiariti, Michele
Puddu, Paolo Emilio
المصدر
العدد
المجلد 2011، العدد 2011 (31 ديسمبر/كانون الأول 2011)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2011-07-09
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Antiplatelet treatment in patients with an acute coronary syndrome (ACS), without or with ST segment elevation myocardial infarction (STEMI), forces to keep the balance between potential threats and optimal clinical advantages.
Apart from clopidogrel, glycoprotein (GP) IIb/IIIa inhibitors (abciximab and 2 small molecules, tirofiban and eptifibatide) have come to the clinical scene.
Recent evidence (2009–2011) is reviewed pointing to pharmacoeconometric considerations of concern in times of budget restrictions worldwide.
In ACS, when clopidogrel plus aspirin are on, there might be no advantage to add small molecules.
Whereas in STEMI patients treated by primary PCI, all 3 GP IIb/IIIa antagonists might be superimposable, when only ACS is present and PCI is elective, definite distinction among the 3 agents, both pharmacoeconomically and pharmacodynamically, might be invoked.
There are still points open to debate.
Among these the route (upstream versus downstream) is still a matter of uncertainties.
Moreover, theoretically, there might be differences not only between abciximab and small molecules (mostly superimposable) but also between tirofiban and eptifibatide (the former being potentially more potent).
Thus, a long way is needed before a prominent agent among GPIIb/IIIa inhibitors may be selected.
The game is still open, a role will be played soon by new agents.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Puddu, Paolo Emilio& Schiariti, Michele& Bugiardini, Raffaele. 2011. Glycoprotein IIbIIIa Antagonists in Acute Coronary Syndromes Undergoing PCI : A Long Way to Select Optimal Agent and Route. ISRN Vascular Medicine،Vol. 2011, no. 2011, pp.1-9.
https://search.emarefa.net/detail/BIM-449029
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Puddu, Paolo Emilio…[et al.]. Glycoprotein IIbIIIa Antagonists in Acute Coronary Syndromes Undergoing PCI : A Long Way to Select Optimal Agent and Route. ISRN Vascular Medicine No. 2011 (2011), pp.1-9.
https://search.emarefa.net/detail/BIM-449029
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Puddu, Paolo Emilio& Schiariti, Michele& Bugiardini, Raffaele. Glycoprotein IIbIIIa Antagonists in Acute Coronary Syndromes Undergoing PCI : A Long Way to Select Optimal Agent and Route. ISRN Vascular Medicine. 2011. Vol. 2011, no. 2011, pp.1-9.
https://search.emarefa.net/detail/BIM-449029
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-449029
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر